El tratamiento "HiCy" reversa los síntomas de la esclerosis múltiple en pacientes selectosContributed by: Anonymous · Views: 1,102
Contributed by: Anonymous · June 11, 2008 @ 10:01 AM MDT · Views: 1,102
“HICY” DRUG REGIMEN REVERSES MS SYMPTOMS IN SELECTED PATIENTS--New approach to immunosuppressant treatment tested in nine individuals shows promise
A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report. The findings in nine people, most of whom had failed all other treatments, suggest new ways to treat a disease that tends to progress relentlessly.
“We didn’t expect such a dramatic return of function,” says Douglas Kerr, M.D., Ph.D, associate professor of neurology at the Johns Hopkins University School of Medicine. “Although we’re very early in the game, we think this approach could be the linchpin of a significant advance for MS treatment.”
Researchers have used the so called HiCy treatments with some success at Johns Hopkins for a variety of other immune system disorders, including aplastic anemia, lupus and myasthenia gravis.
Cyclophosphamide kills immune-system cells but spares the bone marrow stem cells that make them. The usual method of delivering it in pulsed, small doses, however, can cause the drug to build up to toxic concentrations in patients’ bodies, causing a variety of side effects, including a greatly increased risk of infection.
Seeking an alternative way to use the drug, Kerr and his colleagues reasoned that HiCy might clear out the majority of a patient’s immune system in one fell swoop, then allow it to “reboot,” giving nerve cells a fresh start and an opportunity to repair themselves. In the current study, nine MS patients got a total single infusion of 200 milligrams per kilogram of cyclophosphamide intravenously over four days, a dose several times higher than that given in pulsed regimens but significantly lower than the total amount usually given patients over time.
Before treatment, Kerr says, the study participants were “the worst of the worst” among MS patients. Eight of the nine patients had failed conventional MS treatments, and several of them were wheelchair-bound.
Reporting in the June 9 Archives of Neurology, the Johns Hopkins team said the disease appeared to reverse course for seven of the nine patients over two years following treatments. Overall, the patients, men and women ranging in age from 20 to 47 at the beginning of the study, experienced a 40 percent reduction in scores of a standard test that measures disability. They also had an overall 87 percent improvement in scores on a composite test that measures physical and mental function.
MS, which affects approximately 400,000 people - predominantly women - in the United States, is believed to occur when the body’s immune system attacks the insulating sheath that coats nerve cells, causing it to degenerate. Consequently, electrical signals that the cells use to communicate with the rest of the body become progressively weaker, leading to symptoms that include numbness, tingling, cognitive problems and sometimes paralysis.
Researchers have identified four different subtypes of MS, and each is thought to be caused by a different autoimmune process. As a result, developing a treatment that effectively targets all types of MS has been challenging, says Kerr.
Kerr cautions that the “reboot” phenomenon didn’t work in all the patients. Two years after treatment, MRI images showed that the disease had reactivated in about half the study participants, suggesting that their renewed ability may not be permanent.
Kerr’s colleague Adam Kaplin, M.D., Ph.D., assistant professor of psychiatry and neurology at the Johns Hopkins School of Medicine, is leading efforts to improve HiCy therapy with a blood test in development that could predict which patients would benefit the most from HiCy treatment. Also, since immune cells that regrow after HiCy treatment may contain the same defect that leads to MS, Kaplin and his colleagues are working on a way to regrow only healthy immune cells.
Other Hopkins researchers who participated in this study include Chitra Krishnan, M.H.S., Robert A. Brodsky, M.D., Daniel B. Drachman, M.D., Richard J. Jones, M.D., Dzung L. Pham, Ph.D., Nancy D. Richert, M.D., Ph.D., Carlos A. Pardo, M.D., David M. Yousem, M.D., M.B.A., Edward Hammond, M.D., M.P.H., Megan Quigg, B.A., Carrilin Trecker, B.A., Justin C. McArthur, M.B.B.S., M.P.H., Avindra Nath, M.D., Benjamin M. Greenberg, M.D., M.H.S., and Peter A. Calabresi, M.D.
This research was supported by the General Clinical Research Center of the Johns Hopkins School of Medicine, a National Multiple Sclerosis Society grant, philanthropic support from Mr. Alvin Myerberg, and the Johns Hopkins Project RESTORE.
Under a licensing agreement between Accentia Pharmaceuticals and the Johns Hopkins University, Drs. Brodsky and Jones and the University are entitled to royalty on sales of a method of administering high dose cyclophosphamide. The study described in this press release could impact the value of this method of administering the drug. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
Media Contact: Christen Brownlee 410-955-7832; firstname.lastname@example.org
Credits: Johns Hopkins Medicine